Foundational Platform
Intercept IQ™
The molecular substrate behind every Kihealth programme — cell-free DNA, beta-cell methylation signatures and AI-driven tissue-of-origin inference.
EUROPEAN DIVISION
Building the Future of Metabolic Disease Detection
Kihealth Europe is pioneering a new category of molecular diagnostics focused on identifying the biological changes that precede Type 1 Diabetes, Type 2 Diabetes, and metabolic disease — helping move healthcare from disease management to disease prevention.
Metabolic DiseaseType 1 DiabetesType 2 Diabetes
The Problem · Part I
Type 1 Diabetes — a lifelong disease that arrives without warning.
Type 1 Diabetes is an autoimmune disease that silently destroys pancreatic beta-cells for months or years before the first symptom. It is rising fastest in children — and by the time it is diagnosed, most of the pancreas has already been lost.
8.75M
People worldwide living with Type 1 Diabetes today.
+4%
Annual increase in Type 1 Diabetes incidence in children globally.
70–80%
Beta-cell mass typically lost before diagnosis is made.
30–60%
Children presenting in diabetic ketoacidosis at first diagnosis.
13 yrs
Estimated life-years lost when Type 1 Diabetes is diagnosed in childhood.
2× risk
Cardiovascular mortality vs. non-diabetic peers over the lifespan.
Sources: IDF Diabetes Atlas (10th ed.), JDRF T1D Index, published clinical literature on beta-cell decline.
The Problem · Part II
Type 2 Diabetes — the world's largest chronic disease.
Type 2 Diabetes now affects roughly one in ten adults on Earth. It advances silently through pre-diabetes and beta-cell stress for a decade or more before glucose finally rises — and hundreds of millions remain undiagnosed.
529M
Adults living with Type 2 Diabetes worldwide today.
1 in 10
Adults globally now living with diabetes — the vast majority Type 2.
44%
Of adults with diabetes remain undiagnosed and untreated.
541M
Adults living with impaired glucose tolerance — pre-diabetes.
10–12 yrs
Typical duration of undetected beta-cell decline before diagnosis.
2–4× risk
Increased risk of heart attack, stroke and kidney failure.
Sources: IDF Diabetes Atlas (10th ed.), WHO Global Report on Diabetes, The Lancet Global Burden of Disease.
The Problem · Part III
The global burden — a trillion-dollar strain on health systems.
Diabetes and metabolic disease together account for more health expenditure than any other chronic condition on the planet — and the curve is still climbing. Every year of earlier detection compounds into decades of avoided cost, complication and suffering.
$966B
Global diabetes health expenditure in 2021 — up 316% over 15 years.
$1.05T
Projected annual diabetes health expenditure by 2045.
$412B
Annual cost of diagnosed diabetes in the United States alone.
€200B+
Estimated annual diabetes-related spend across the European Union.
6.7M
Deaths attributed to diabetes and its complications each year.
537M
Adults with diabetes today — projected to reach 783M by 2045.
1 in 6
Global healthcare euros now spent on diabetes-related care.
2.2B
Adults worldwide living with overweight or obesity — the metabolic pipeline.
Sources: IDF Diabetes Atlas (10th ed.), American Diabetes Association Economic Cost Report, WHO Global Report on Diabetes, OECD Health at a Glance, World Obesity Federation.
By the time disease declares itself, the damage — and the cost — is already done.
Kihealth Europe exists to move detection upstream, before symptoms and before spend compounds.
The Solution
Intercept disease at the molecular threshold — before symptoms appear.
The InterceptIQ™ platform is designed to detect active disease biology from a routine blood draw. By reading cell-free DNA and epigenetic signals released by injured beta cells, we aim to intercept Type 1 Diabetes, Type 2 Diabetes and metabolic disease near onset — when biology may still be modifiable, and long before downstream complications accumulate.
What We Measure
Active beta-cell death — the earliest molecular signal
Traditional biomarkers like HbA1c and glucose only move once significant beta-cell mass is already lost. Demethylated INS cfDNA — released when beta cells die — rises years earlier, opening a window of opportunity to intervene before irreversible loss.
Window of Opportunity
Beta-cell death is detectable while functional mass and HbA1c still read as normal.
HbA1c
Stable early, rising sharply only once significant beta-cell loss has occurred.
Functional Beta-Cell Mass
Largely preserved through the window of opportunity, then declines once clinical dysfunction begins.
% Demethylated INS cfDNA
Rises first — peaking inside the window — then declines as the at-risk reserve is depleted.
Traditional Biomarkers Remain Stable
HbA1c and glucose often stay within the normal range while silent beta-cell injury is already underway.
Kihealth Detects Active Beta-Cell Death
Demethylated INS cfDNA rises as beta cells undergo apoptosis — a direct, earlier molecular signal.
Intervene Before Irreversible Loss
Earlier detection opens the window to preserve functional beta-cell mass before substantial loss has occurred.
The Interception Window
The biological window we have been missing.
Between the first molecular signs of beta-cell injury and the appearance of clinical symptoms lies a silent biological window — measurable, potentially actionable, and previously invisible to routine diagnostics.
- 01Autoimmune or metabolic stressPre-clinical biology
- 02Beta-cell injury beginscfDNA fragments releasedKIHEALTH DESIGNED TO DETECT
- 03Compensation declinesInsulin reserve drops
- 04Glucose risesMetabolic threshold crossed
- 05Clinical symptoms appearStandard diagnosis
Beta-Cell Biology
The cell at the centre of diabetes
Beta cells produce insulin and maintain glucose control. Their dysfunction and loss are the central events driving both Type 1 and Type 2 Diabetes.
- Healthy Beta Cells
- Beta Cell Stress
- Beta Cell Dysfunction
- Beta Cell Death
- Diabetes Progression
Stage 01
Islet · β-cell
Insulin reserve · 100%
cfDNA · Quiet
Stage 01 of 5
Healthy Beta Cells
Insulin granules are abundant, the membrane is intact, glucose sensing is precise. The pancreas maintains metabolic balance silently in the background.
The takeaway
Diabetes is fundamentally a disease of beta-cell dysfunction and loss. Measure the cell, and you measure the disease — before it declares itself.
The InterceptIQ™ Platform
One platform. Multi-omics. AI-powered.
BetaIntercept™ is built on the InterceptIQ™ platform, which unites multi-omics data with the KI Intelligence AI engine to detect active disease biology from a routine blood draw — before clinical symptoms appear.
See the platform architectureL1 · Wet Lab
Capture
Low-input library chemistry designed to preserve fragmentomic and methylation detail from picogram-level cell-free DNA.
L2 · Multi-omics
Sequence
Whole-genome bisulfite sequencing and multi-omics profiling tuned for cfDNA fragment biology, with quality-audited basecalling.
L3 · Bioinformatics
Decode
Reproducible pipelines decoding methylation, fragmentomic and end-motif signal at single-molecule resolution.
L4 · KI Intelligence
Infer
KI Intelligence AI engine being investigated to jointly resolve tissue-of-origin and disease state, with calibrated probability outputs.
L5 · Clinical
Deliver
Physician-facing reports being developed under accredited laboratory standards and delivered through standards-based interfaces.
Pipeline
Programmes across the disease spectrum
Type 1 Diabetes
BetaIntercept™ T1D
Beta-cell unmethylated INS cfDNA designed to evaluate active immune-mediated beta-cell destruction across Stage 1–3 Type 1 Diabetes.
Type 2 Diabetes
BetaIntercept™ T2D
Multi-tissue metabolic methylation panel surfacing beta-cell stress and dysfunction long before traditional markers move.
Forward Programme
Future Metabolic Health Applications
Forward-looking research extending Intercept IQ™ into adjacent metabolic indications where beta-cell biology offers a measurable signal.
Featured Programme
BetaIntercept™: a molecular view of beta-cell biology
Traditional diabetes monitoring relies on glucose, HbA1c, insulin and C-peptide — markers that typically reflect metabolic dysfunction after substantial biological change has already occurred.
BetaIntercept™ is designed to evaluate biological signals associated with pancreatic beta-cell health, providing insight into processes being investigated that may precede traditional markers of progression.
Why Kihealth Europe
Earlier signal. Better decisions. Better outcomes.
Earlier Detection
Measuring biology before symptoms — when intervention may be most effective.
Better Decisions
Designed to surface the active biology driving disease, improving clinical decision-making and supporting development of better interventions.
Better Outcomes
Supporting research into disease while it may remain reversible, and monitoring response over time.
Protecting Children in Europe
Helping curb the progression of type 1 diabetes across Europe, so more children and families never have to face a diagnosis.